Lazard Asset Management
PRME icon

Lazard Asset Management’s Prime Medicine PRME Stock Holding History

Lazard Asset Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,844
Closed -$37.6K – 2045
2025
Q4 		$37.6K Buy
+10,844
New +$48.2K ﹤0.01% 1806
2025
Q1 		– Sell
-26
Closed – – 2519
2024
Q4 		$0 Hold
26
– – ﹤0.01% 2478
2024
Q3 		$0 Sell
26
-46
-64% -$213 ﹤0.01% 2413
2024
Q2 		$0 Sell
72
-1,042
-94% -$6.32K ﹤0.01% 2386
2024
Q1 		$7K Sell
1,114
-618
-36% -$4.69K ﹤0.01% 1887
2023
Q4 		$15K Buy
1,732
+62
+4% +$478 ﹤0.01% 2074
2023
Q3 		$15K Buy
1,670
+66
+4% +$857 ﹤0.01% 2129
2023
Q2 		$23K Buy
1,604
+57
+4% +$796 ﹤0.01% 2076
2023
Q1 		$18K Buy
+1,547
New +$25.2K ﹤0.01% 2073

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Lazard Asset Management's PRME Position: Q1 2026 in Review

Lazard Asset Management sold out of Prime Medicine (PRME) in Q1 2026, closing a stake of 10,844 shares — an estimated $37.6K sold.

Lazard Asset Management first reported a position in PRME in Q1 2023 and held it in 9 quarters. The position peaked at $37.6K in Q4 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Lazard Asset Management reported no remaining Prime Medicine position as of Q1 2026 after selling out during the quarter.
  • Lazard Asset Management sold 10,844 Prime Medicine shares in Q1 2026, an estimated $37.6K.
  • Lazard Asset Management first reported a position in Prime Medicine in Q1 2023 and held it in 9 quarters.
  • Lazard Asset Management's Prime Medicine position peaked at $37.6K in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.